News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Metaphore Pharmaceuticals, Inc. To Present At The CIBC World Markets Annual Biotechnology And Specialty Pharmaceutical Conference



10/19/2005 5:13:10 PM

FORT LEE, N.J., March 31 /PRNewswire/ -- Metaphore Pharmaceuticals, Inc., an emerging pharmaceutical company developing drugs for the treatment of pain, autoimmune disorders and inflammation, today announced that Robert A. Medve, M.D., Senior Vice President, Development, will present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceutical Conference.

The conference will be held at the Millennium Broadway Hotel located at 145 West 44th Street, New York City. Dr. Medve's presentation will take place from 3:15 to 3:45 p.m. ET on Tuesday, April 5, 2005 in Rooms 3.04/3.05. A break out session will follow the presentation.

A live and archived audio Webcast of the event will be available on Metaphore's Web site, http://www.metaphore.com/ . From the home page, click on the CIBC World Markets Annual Biotechnology and Specialty Pharmaceutical Conference Presentation link. Please log on five minutes prior to the event to ensure the proper software is downloaded and installed.

More about the Company

Metaphore Pharmaceuticals, Inc. is a privately held, emerging pharmaceutical company which discovers, develops and will market drugs that prevent and treat pain, autoimmune disorders and inflammation. The company leverages its expertise in chemistry and biology to discover and develop small molecule compounds that mimic the activity of human enzymes. Metaphore's lead compounds mimic the function of superoxide dismutase (SOD), a beneficial enzyme that serves an important protective role in the body by removing superoxide, a toxic free radical that can damage cells and tissues. Superoxide anions are implicated in a variety of diseases associated with pain and inflammation.

Metaphore has a global, multilayered intellectual property estate, stemming both from in-licensing and internal research, with claims to compounds, compositions of matter, methods of treatment and methods of making. The patent estate includes 10 issued US patents, 59 foreign patents, and 66 applications pending worldwide, including 20 in the US.

Product candidates in U.S. clinical testing have broad therapeutic potential across a variety of diseases. Metaphore currently focuses its clinical development efforts in pain, rheumatoid arthritis and inflammatory disorders. These markets are significant in terms of scope and size. The company maintains offices in Fort Lee, New Jersey and St. Louis, Missouri. For more information on Metaphore, please visit the Web site at: http://www.metaphore.com/.

This press release contains forward-looking statements based on information available to Metaphore as of the date hereof. In some cases, you can identify these forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other comparable terminology. Metaphore's actual results could differ materially from the results stated or implied by such forward-looking statements due to a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, general economic and business conditions, changes in governmental laws and regulations relating to the development and commercialization of pharmaceutical products, and competition in our industry. In addition, we are developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Metaphore disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Metaphore Pharmaceuticals, Inc.

CONTACT: Alan W. Dunton, M.D., President and Chief Executive Officer,+1-201-582-5000, adunton@metaphore.com, or Sara E. K. Cooper, Director ofCorporate Communications, +1-201-582-5000, scooper@metaphore.com, both ofMetaphore Pharmaceuticals; or Scott M. Solomon, Vice President of SharonMerrill Associates, Inc., +1-617-542-5300, ssolomon@InvestorRelations.com; orMatt Dallas, Vice President, Financial Dynamics, +1-212-850-5627,mdallas@fd-us.com, both for Metaphore Pharmaceuticals


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES